Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07145255 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
A Phase 1 study of Breast Cancer and Colo-rectal Cancer, sponsored by MBrace Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 7
- Study locations
NCT07145255 is a Phase 1 study of Breast Cancer and Colo-rectal Cancer that is actively recruiting participants, run by MBrace Therapeutics. The registered enrollment target is 150 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT07145255, a Phase 1 study of Breast Cancer and Colo-rectal Cancer, is actively recruiting participants, sponsored by MBrace Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
Conditions Studied
Interventions
- DRUG ADC
Study Locations (7)
Texas
- NEXT, Dallas - Irving
- START San Antonio - San Antonio
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Michigan
- START, Midwest - Grand Rapids
New Jersey
- START, Astera - East Brunswick
Utah
- START, Mountain Region - West Valley City
Virginia
- NEXT, Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-09-03 |
| Est. Completion | 2029-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07145255
The ClinicalTrials.gov registry entry for NCT07145255 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is MBrace Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which ADC is the first listed.
NCT07145255 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Texas, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT07145255 about?
NCT07145255 is a clinical study titled "Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors". This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
What is the current status of trial NCT07145255?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2025-09-03. Estimated completion is 2029-12-30.
What conditions does trial NCT07145255 study?
This clinical trial studies the following conditions: Breast Cancer, Colo-rectal Cancer, Lung Cancer, Non-Small Cell, Prostate Cancer Castration-resistant Prostate Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma.
What interventions are being tested in trial NCT07145255?
The interventions under investigation include: ADC (DRUG).
Who is sponsoring clinical trial NCT07145255?
This trial is sponsored by MBrace Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07145255 being conducted?
This trial has 7 study locations across California, Michigan, New Jersey, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.